List of Excipients in Branded Drug CARDURA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Roerig	CARDURA	doxazosin mesylate	0049-2710	CELLULOSE ACETATE
Roerig	CARDURA	doxazosin mesylate	0049-2710	FERRIC OXIDE RED
Roerig	CARDURA	doxazosin mesylate	0049-2710	FERROSOFERRIC OXIDE
Roerig	CARDURA	doxazosin mesylate	0049-2710	HYPROMELLOSE
Roerig	CARDURA	doxazosin mesylate	0049-2710	MAGNESIUM STEARATE
Roerig	CARDURA	doxazosin mesylate	0049-2710	POLYETHYLENE GLYCOL

Cardura Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Cardura contains doxazosin mesylate and has two distinct product platforms: immediate-release Cardura tablets and extended-release Cardura XL tablets. The immediate-release product is a mature generic market with low formulation barriers. Cardura XL has greater technical differentiation because its controlled-release system depends on osmotic delivery and is harder to replicate consistently.

The strongest commercial opportunities are lactose-free immediate-release tablets, orally disintegrating or liquid presentations for selected patients, low-cost global generic manufacturing, and technically robust extended-release products. Excipients can improve manufacturability, patient acceptability, and supply-chain resilience, but they generally do not create meaningful standalone exclusivity.

What is Cardura and which dosage forms are commercially relevant?

Cardura is the brand name for doxazosin mesylate, an alpha-1 adrenergic antagonist approved for hypertension and the signs and symptoms of benign prostatic hyperplasia, or BPH. Cardura is marketed in immediate-release tablets. Cardura XL is an extended-release formulation for hypertension and BPH-related symptoms in certain markets.

Product	Active ingredient	Release profile	Primary use	Commercial status
Cardura tablets	Doxazosin mesylate	Immediate release	Hypertension, BPH	Mature brand and generic market
Cardura XL	Doxazosin mesylate	Extended release	Hypertension, BPH	Technically differentiated, limited market visibility
Generic doxazosin tablets	Doxazosin mesylate	Immediate release	Hypertension, BPH	Broad generic competition
Compounded doxazosin liquids	Doxazosin mesylate	Immediate release	Patient-specific use	Niche, pharmacy-dependent

FDA approved Cardura for hypertension in 1990 and later expanded its labeling to BPH. Cardura XL received U.S. approval in 2005. The key commercial distinction is that immediate-release doxazosin is an established, low-cost product, while extended-release doxazosin requires more complex formulation and release-control work.[1][2]

What excipients are used in Cardura tablets?

The immediate-release Cardura tablet platform uses conventional solid-dose excipients. FDA labeling identifies excipients including lactose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, and sodium lauryl sulfate, with tablet-color excipients varying by strength.[1]

Excipient class	Representative Cardura function	Formulation purpose
Lactose	Diluent	Adds bulk and supports tablet compression
Microcrystalline cellulose	Diluent and dry binder	Improves compactibility and tablet strength
Sodium starch glycolate	Superdisintegrant	Promotes tablet breakup after administration
Magnesium stearate	Lubricant	Reduces tooling friction and ejection force
Sodium lauryl sulfate	Wetting agent	Supports wetting and powder dispersion
Colorants	Appearance and strength identification	Supports dose differentiation

This composition is commercially attractive because it relies on widely available, compendial materials. A generic manufacturer does not need to reproduce every excipient quantitatively if the product meets the applicable quality, dissolution, stability, and bioequivalence requirements.

What are the main excipient risks in immediate-release Cardura?

The principal risks are manufacturing and patient-acceptability issues rather than intellectual-property barriers.

Lactose creates a market-access constraint for patients with lactose intolerance, milk-related concerns, or preferences for lactose-free medicines. It is not normally a clinical barrier at the small quantities used in tablets, but lactose-free positioning can support product differentiation in selected markets.

Magnesium stearate can affect powder flow, tablet ejection, and dissolution if over-lubrication occurs. The risk is more important for high-speed compression than for the underlying Cardura brand concept.

Sodium starch glycolate is sensitive to formulation composition and process conditions. Excessive compression force, excessive lubricant, or poor disintegrant distribution can delay tablet disintegration.

Sodium lauryl sulfate can improve wetting but may create tolerability, taste, or label-preference concerns. A manufacturer can often remove or replace it if dissolution and content uniformity remain acceptable.

What excipient strategy is optimal for generic doxazosin tablets?

A practical generic strategy is a robust, lactose-free, direct-compression formulation using microcrystalline cellulose, a modern superdisintegrant, a low-use lubricant, and a wetting aid only when dissolution data justify it.

Recommended formulation objectives

Objective	Preferred strategy	Commercial benefit
Lactose-free positioning	Replace lactose with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a combination	Expands patient and market positioning
Fast disintegration	Use croscarmellose sodium, crospovidone, or sodium starch glycolate	Supports rapid dissolution
Stable compression	Use engineered or silicified microcrystalline cellulose	Improves flow and tablet strength
Lower lubricant sensitivity	Optimize magnesium stearate level and blending time	Reduces dissolution variability
Global manufacturing	Select excipients with broad pharmacopoeial coverage	Simplifies multi-country registration
Supply resilience	Qualify at least two suppliers for critical excipients	Reduces interruption risk

Mannitol can support a lactose-free formulation and improve mouthfeel, although it is more expensive than lactose. Dibasic calcium phosphate can improve density and flow but may complicate dissolution and compression when used at high levels. Crospovidone is often useful where rapid wicking and low swelling are preferred. Croscarmellose sodium can provide strong disintegration but requires careful control of concentration and distribution.

A formulation should avoid unnecessary excipient complexity. Each added excipient increases supplier qualification, analytical testing, extractables and leachables exposure, and regulatory documentation.

What formulations are protected by Cardura and Cardura XL?

The immediate-release Cardura formulation has limited remaining commercial exclusivity value. The product’s principal patents and regulatory exclusivities expired years ago, and multiple generic doxazosin products have reached the market.

Cardura XL is more formulation-dependent. Its extended-release system uses a controlled-release tablet architecture in which excipients regulate water uptake, swelling, and drug release. The product is associated with an osmotic delivery approach rather than a simple matrix tablet. Relevant excipient categories include:

• Osmotic agents such as sodium chloride.
• Swellable polymers such as polyethylene oxide.
• Membrane-forming polymers such as cellulose acetate.
• Pore-forming or membrane-modifying components.
• Plasticizers and coating aids.
• Opacifiers and colorants.

The commercial barrier is process control. The manufacturer must control tablet core composition, membrane weight gain, coating uniformity, laser orifice performance where applicable, and dissolution across multiple pH conditions.

Excipients alone normally do not provide strong exclusivity. Patentable value may arise from the combination of polymer grade, osmogen concentration, membrane permeability, delivery-orifice design, manufacturing sequence, dissolution profile, and dose proportionality.

When did Cardura lose exclusivity?

Cardura’s original small-molecule exclusivity expired long before the current generic market formed. The immediate-release product is therefore a post-exclusivity product with substantial price competition.

Milestone	Approximate timing	Commercial effect
FDA approval of Cardura for hypertension	1990	Originator launch
BPH indication expansion	Mid-1990s	Broadened prescribing base
Generic immediate-release entry	2000s	Price erosion and supplier expansion
Cardura XL approval	2005	Extended-release differentiation
Current market phase	Mature	Low brand pricing power; formulation niches remain

The exact patent expiration dates depend on the patent family, jurisdiction, pediatric extensions, terminal disclaimers, and any listed formulation patents. The central business conclusion is unchanged: immediate-release doxazosin is no longer protected by commercially meaningful originator exclusivity.

What is the Orange Book status of Cardura?

The Orange Book is the principal FDA source for approved products, therapeutic-equivalence evaluations, and listed patents or exclusivity information.[3] Immediate-release Cardura and generic doxazosin tablets are evaluated through the abbreviated new drug application pathway.

For a generic sponsor, the regulatory focus is usually:

1. Pharmaceutical equivalence.
2. Bioequivalence.
3. Content uniformity and assay.
4. Dissolution across relevant media.
5. Stability.
6. Manufacturing controls.
7. Labeling consistency.

Cardura XL requires a separate analysis because an extended-release product may need more demanding bioequivalence and in vitro release characterization. A sponsor cannot assume that an immediate-release doxazosin approval provides a regulatory shortcut for an extended-release product.

Which companies are challenging Cardura exclusivity?

Generic competition has historically come from multiple manufacturers of doxazosin mesylate tablets. The relevant competitive set includes large U.S. generic companies, global suppliers, and contract manufacturers that can produce low-cost immediate-release tablets.

The market is less defined by a single Paragraph IV challenger than by cumulative generic entry over time. Paragraph IV certifications would have been most commercially important during the original patent period. Today, the principal competitive tools are:

• Lower manufacturing cost.
• Reliable supply.
• Broad dosage-strength availability.
• State and payer formulary access.
• Private-label and institutional contracts.
• Specialized dosage forms.

No biosimilar risk applies. Doxazosin is a chemically synthesized small molecule, not a biologic. Competition proceeds through abbreviated generic pathways rather than biosimilar applications.

What patent litigation and settlement issues affect Cardura?

The principal litigation exposure is historical patent litigation surrounding generic entry and extended-release formulation rights. For current commercial planning, the relevant legal risks are more likely to involve:

• Product-specific formulation patents.
• Process patents for controlled-release tablets.
• Trade secrets relating to coating and release testing.
• Supplier confidentiality and manufacturing know-how.
• Patent challenges to any newly developed liquid, orally disintegrating, or modified-release product.

A generic immediate-release sponsor has a relatively low freedom-to-operate risk if it avoids protected extended-release architecture and uses a conventional formulation. An extended-release sponsor faces greater risk because release-control systems can create overlapping claims covering polymers, membrane structures, coating methods, and dissolution profiles.

Settlement agreements, if any, should be assessed for entry dates, authorized-generic provisions, supply obligations, and restrictions on dosage forms. They are most relevant when a listed patent remains enforceable. For the mature immediate-release Cardura market, settlement-driven delayed entry is not the primary commercial issue.

How strong is the Cardura patent estate?

The legacy immediate-release estate is weak as a current commercial barrier. The technical formulation is conventional, the active ingredient is well known, and generic products have broad market presence.

Cardura XL has a stronger technical estate than immediate-release Cardura, but the strength is reduced by:

• Age of the original product and patents.
• Availability of alternative controlled-release technologies.
• The ability to design around particular polymer or coating claims.
• The difficulty of sustaining premium pricing in a mature alpha-blocker category.
• Limited prescriber urgency to switch from low-cost immediate-release products.

Patent-estate dimension	Immediate-release Cardura	Cardura XL
Active-ingredient protection	Expired	Expired
Excipient complexity	Low	Moderate to high
Design-around potential	High	Moderate
Manufacturing know-how value	Low to moderate	High
Generic entry barrier	Low	Higher
Premium pricing potential	Low	Limited and indication-dependent

What commercial opportunities exist for Cardura excipients?

Lactose-free immediate-release tablets

A lactose-free formulation is the clearest low-risk opportunity. It can support pharmacy substitution, institutional procurement, and markets where lactose-free labeling is valued. The product should preserve rapid dissolution and avoid a meaningful increase in tablet size.

Orally disintegrating tablets

An orally disintegrating doxazosin product could target patients with dysphagia, elderly patients, and individuals who have difficulty taking conventional tablets. The primary challenges are dose uniformity, taste masking, friability, moisture sensitivity, and bioequivalence.

Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking systems may be relevant. The commercial opportunity is niche because doxazosin is not an acute rescue medicine and tablets are inexpensive.

Oral liquid or powder-for-reconstitution products

A liquid formulation could serve patients who cannot swallow tablets, including selected long-term-care and extemporaneous-compounding populations. The central technical issues are chemical stability, preservative compatibility, adsorption to packaging, uniform dosing, and palatability.

The opportunity is stronger for specialty pharmacies and institutional channels than for mass retail.

Improved extended-release products

A new controlled-release doxazosin product could reduce peak-related adverse effects, simplify dosing, or improve adherence. The commercial case depends on clinical or pharmacokinetic differentiation. A simple reformulation without measurable patient benefit would face weak pricing power.

Excipient supply opportunities

Suppliers can pursue value through:

• Direct-compression grades of microcrystalline cellulose.
• Co-processed excipients for lactose-free tablets.
• Low-peroxide polymer grades for modified release.
• Controlled-particle-size mannitol.
• Functional coating systems.
• Ready-to-use osmotic coating platforms.
• Stability-indicating excipient packages for global filings.

The strongest supplier opportunity is not ownership of Cardura-specific IP. It is qualification as a reliable, multi-region source for excipients used in generic doxazosin manufacturing.

How does Cardura compare with competing alpha-blockers?

Doxazosin competes with terazosin, tamsulosin, alfuzosin, and silodosin. Tamsulosin and silodosin have stronger differentiation in BPH prescribing because of uroselectivity. Doxazosin and terazosin remain relevant where cost, hypertension treatment, or broad alpha-1 blockade is important.

Product	Active ingredient	Main formulation opportunity	Market position
Cardura	Doxazosin	Low-cost lactose-free or patient-friendly dosage forms	Mature
Hytrin	Terazosin	Immediate-release and capsule differentiation	Mature
Flomax	Tamsulosin	Modified-release capsule and generic supply	Strong BPH competition
Uroxatral	Alfuzosin	Extended-release tablet	BPH-focused
Rapaflo	Silodosin	Capsule and tolerability positioning	More differentiated BPH segment

Doxazosin has a lower formulation barrier than many modified-release competitors. Its main advantage for a generic sponsor is manufacturing simplicity, not patent strength.

What generic launch scenarios exist for Cardura?

Low-cost immediate-release launch

This is the most practical scenario. A sponsor can use conventional excipients, produce all major strengths, and compete through supply reliability and contract pricing. Margins will be limited by established generic competition.

Premium lactose-free launch

This approach can support modest differentiation but is unlikely to command a large premium without payer or pharmacy-channel support.

Patient-friendly dosage form

An orally disintegrating tablet or liquid can target underserved patients. The market is smaller, but competition may be less intense.

Extended-release re-entry

A Cardura XL-type product offers greater technical differentiation but requires more development capital, bioequivalence work, and manufacturing validation. The opportunity is attractive only if the sponsor can identify a defensible clinical or adherence benefit.

Key Takeaways

• Cardura is doxazosin mesylate, an established small-molecule alpha-1 blocker.
• Immediate-release Cardura has a mature generic market and limited current patent leverage.
• Cardura tablet excipients are conventional: lactose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, and sodium lauryl sulfate are identified in FDA labeling.
• The strongest immediate-release opportunity is a lactose-free, direct-compression tablet with robust dissolution and dual-source excipients.
• Cardura XL has greater technical complexity because its release profile depends on osmotic and polymeric delivery components.
• Excipients provide manufacturing and market-positioning advantages but rarely create meaningful standalone exclusivity.
• No biosimilar pathway applies because doxazosin is a synthetic small molecule.
• Commercial value is concentrated in reliable supply, institutional contracts, patient-friendly dosage forms, and technically differentiated modified release.
• Revenue exposure is likely limited at the originator level because Cardura is a mature product and is not generally reported as a separately material branded franchise by Pfizer.

FAQs

Can lactose-free doxazosin tablets be patent protected?

The excipient substitution alone is unlikely to support a strong patent position. Protection may be possible if the formulation produces an unexpected dissolution, stability, manufacturability, or bioavailability result.

Is Cardura XL easier to genericize than other extended-release alpha-blockers?

Not necessarily. Its osmotic or polymer-controlled release design creates meaningful manufacturing and bioequivalence requirements, even though the active ingredient is old.

Can a manufacturer use the same excipients as Cardura?

A manufacturer can generally use the same public-label excipients, provided the finished product satisfies FDA quality, bioequivalence, dissolution, stability, and labeling requirements.

Is there a commercial opportunity for pediatric doxazosin liquid?

A liquid may have a compounding or specialty-pharmacy opportunity, but pediatric use requires appropriate clinical, regulatory, stability, and labeling support. It is not automatically equivalent to an FDA-approved pediatric product.

Which excipient has the greatest strategic value in Cardura XL?

The highest-value materials are controlled-grade polymers and coating systems that deliver a reproducible release profile. Their value comes from process performance and supply reliability rather than from the excipient name alone.

References

1. U.S. Food and Drug Administration. (n.d.). Cardura (doxazosin mesylate) tablets: Prescribing information. Drugs@FDA.
2. U.S. Food and Drug Administration. (n.d.). Cardura XL (doxazosin mesylate extended-release tablets): Prescribing information. Drugs@FDA.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-overview-and-introduction